Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

Though things might not go that far, it's still worth planning ahead. Vertex Pharmaceuticals is best known for developing cystic fibrosis (CF) drugs. In patients with this condition, the normally ...

Vertex Pharmaceuticals' approved therapies and pipeline make it especially tariff-resistant. Stocks are sinking the most since the COVID-19-fueled sell-off in 2020. A global trade war seems imminent.

Vertex will not advance VX-264 further in clinical trials. Credit: Andrii Yalanskyi via Getty Images. Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell ...

The clitoris, situated at the entrance of the vagina, houses sensitive tissue or the clitoral glans. It is the organ responsible for female orgasms. The clitoris is mostly inside the body. The ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March. After being in the ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...